We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,766 hedge funds and large institutions have $62.7B invested in Bristol-Myers Squibb in 2018 Q4 according to their latest regulatory filings, with 208 funds opening new positions, 555 increasing their positions, 748 reducing their positions, and 155 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more first-time investments, than exits

New positions opened: 208 | Existing positions closed: 155

2% more funds holding

Funds holding: 1,7301,766 (+36)

0.61% more ownership

Funds ownership: 73.88%74.49% (+0.61%)

1% less call options, than puts

Call options by funds: $1.13B | Put options by funds: $1.14B

2% less funds holding in top 10

Funds holding in top 10: 4241 (-1)

16% less capital invested

Capital invested by funds: $74.8B → $62.7B (-$12.1B)

26% less repeat investments, than reductions

Existing positions increased: 555 | Existing positions reduced: 748

Holders
1,766
Holders Change
+36
Holders Change %
+2.08%
% of All Funds
39.34%
Holding in Top 10
41
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-2.38%
% of All Funds
0.91%
New
208
Increased
555
Reduced
748
Closed
155
Calls
$1.13B
Puts
$1.14B
Net Calls
-$12.3M
Net Calls Change
-$94.7M
Name Holding Trade Value Shares
Change
Change in
Stake
OAM
301
Oppenheimer Asset Management
New York
$11.4M +$425K +7,913 +4%
KCM
302
Kornitzer Capital Management
Kansas
$11.3M -$24.7K -460 -0.2%
WF
303
Welch & Forbes
Massachusetts
$11.2M -$337K -6,263 -3%
MOACM
304
Mutual of America Capital Management
New York
$11.2M +$213K +3,958 +2%
Mirae Asset Global Investments
305
Mirae Asset Global Investments
South Korea
$11M -$1.39M -25,779 -11%
AL
306
Arnhold LLC
New York
$11M +$2.35M +43,694 +26%
FAM
307
Fred Alger Management
New York
$11M -$26.9M -499,840 -70%
DADC
308
D.A. Davidson & Co
Montana
$11M +$164K +3,044 +1%
Cambridge Investment Research Advisors
309
Cambridge Investment Research Advisors
Iowa
$10.8M -$1.26M -23,466 -10%
DILIC
310
Dai-ichi Life Insurance Company
Japan
$10.7M -$581K -10,820 -5%
AG
311
Advisor Group
Arizona
$10.7M +$2.78M +51,686 +33%
HIMCH
312
Hartford Investment Management Co (HIMCO)
Connecticut
$10.7M +$140K +2,612 +1%
CA
313
CapWealth Advisors
Tennessee
$10.7M +$945K +17,592 +9%
HP
314
Hosking Partners
United Kingdom
$10.6M -$406K -7,565 -4%
CM
315
Capital Management
Virginia
$10.5M +$456K +8,481 +4%
TCM
316
Twin Capital Management
Pennsylvania
$10.5M -$121K -2,260 -1%
GAM
317
Griffin Asset Management
New York
$10.4M +$179K +3,337 +2%
AIA
318
Affinity Investment Advisors
California
$10.4M -$954K -17,750 -8%
Rockefeller Capital Management
319
Rockefeller Capital Management
New York
$10.3M +$3.16M +58,786 +42%
TAF
320
Tredje AP-fonden
Sweden
$10.1M -$3.73M -69,452 -26%
DP
321
Dundas Partners
United Kingdom
$9.99M
AIP
322
ARS Investment Partners
New York
$9.91M -$668K -12,441 -6%
ISL
323
Ingalls & Snyder LLC
New York
$9.89M -$397K -7,394 -4%
SYBT
324
Stock Yards Bank & Trust
Kentucky
$9.83M +$7.48M +139,306 +279%
RI
325
Redwood Investments
Massachusetts
$9.64M +$9.97M +185,492 New

BMY Hedge Fund Activity: Q4 2018 in Review

1,766 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2018, worth a combined $62.7B — down 16% from $74.8B a quarter earlier.

Buyers outnumbered sellers: 208 funds opened new BMY positions and 155 closed out — a net gain of 53 holders — while 555 added to existing stakes and 748 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $517M. The largest seller was Jennison Associates, cutting an estimated $558M.

  • 1,766 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2018, up from 1,730 in Q3 2018.
  • Funds reported $62.7B of Bristol-Myers Squibb stock for Q4 2018, down 16% quarter-over-quarter.
  • 208 funds opened new Bristol-Myers Squibb positions in Q4 2018 and 155 closed out, a net change of +53 holders.
  • The largest Bristol-Myers Squibb buyer in Q4 2018 was Dodge & Cox, an estimated $517M added.
  • The largest Bristol-Myers Squibb seller in Q4 2018 was Jennison Associates, an estimated $558M sold.

Based on aggregated 13F filings for Q4 2018.